Spnib 70mg Tablet 60s

Uses of Spnib 70mg Tablet 60s

Dasatinib is a cancer medication that is used to treat certain types of leukemia, including:

• Chronic myeloid leukemia (CML). Dasatinib is used to treat adults and children with CML who have not responded to other treatments, such as imatinib . It is also used to treat newly diagnosed adults with CML in chronic phase.
• Acute lymphoblastic leukemia (ALL). Dasatinib is used to treat adults with ALL who have not responded to other treatments. It is also used in combination with chemotherapy to treat children with ALL who are 1 year of age or older.

rr

Side Effects of Spnib 70mg Tablet 60s

Common side effects of Dasatanib include :

1. Reversible myelosuppression,
2. Neutropenia, anaemia (reduction in red blood cells),
3. Thrombocytopenia (Reduction in thrombocytes in blood)
4. Fluid retention
5. Pulmonary arterial hypertension,
6. Arrhythmias
7. Musculoskeletal pain,
8. GI disturbances,
9. Headache,
10. Chills,
11. Fatigue,
12. Myalgia,
13. Chest pain,
14. Arthralgia (pain in joints),
15. Pyrexia (Fever)
16. Flushing, colitis,
17. Electrolyte disturbances, appetite and wt disturbances, rash, dermatitis, hyperhidrosis, pruritus, acne.

Potentially Fatal side effects include: Severe bleeding events, including fatal CNS and GI haemorrhages; MI.

Drug Interactions

Concomitant use w/ drugs that have narrow therapeutic index (e.g. alfentanil, cisapride, ciclosporin, fentanyl, pimozide, quinidine, simvastatin, sirolimus, tacrolimus, ergot alkaloids) as it may increase the serum levels of these drugs. Increased risk of bleeding and thrombocytopenia w/ antiplatelet drugs, anticoagulants, and NSAIDs. Potentially Fatal: May reduce plasma levels w/ antacids, administer antacid 2 hr apart from the admin of dasatinib. May increase plasma levels w/ CYP3A4 inhibitors (e.g. atazanavir, clarithromycin, erythromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole). May reduce plasma levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenytoin, phenobarbital or rifampicin).

Contraindications

Concomitant use w/ CYP3A4 inhibitors (e.g. atazanavir, clarithromycin, erythromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole or grapefruit juice); CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenytoin, phenobarbital, rifampicin or St John's wort); antacid. Pregnancy.

Mechanism of Action

Dasatinib works by blocking the growth and spread of cancer cells. It does this by targeting a protein called BCR-ABL, which is found in many cancer cells. BCR-ABL is responsible for the uncontrolled growth of cancer cells. By blocking BCR-ABL, dasatinib helps to slow or stop the growth of cancer cells.

Special Precautions

Patients w/ predisposing factors for QT prolongation (e.g. congenital long QT syndrome, hypokalaemia, hypomagnesaemia, on antiarrhythmic therapy, or receiving cumulative high doses of anthracyclines). Hepatic impairment. Lactation. Monitoring Parameters Evaluate patients for manifestations of underlying cardiopulmonary disease prior to and during therapy. Measure full blood counts wkly for the 1st 2 mth and then mthly thereafter.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.